Vyriad, a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, has announced the closing of the $25 million final tranche to its Series B financing, bringing the total Series B round to $85 million. This additional funding supports the imminent first-in-human testing of VV169, Vyriad's in vivo CAR-T candidate, in patients with relapsed or treatment-refractory multiple myeloma.

The Series B, including this latest tranche, was led by Mr. Harry Stine of Stine Seed Farms, Inc., the world's largest private seed company and a technology leader in plant genetics. Several significant family offices also participated.

Vyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company uses engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells. It has ongoing corporate partnerships with Regeneron Pharmaceuticals and Novartis. Vyriad's developmental programs include oncolytic virotherapy, in vivo gene therapy, and gene-editing applications, with ongoing Phase 1-2 trials across multiple cancer indications. Vyriad is a privately held company based in Rochester, Minnesota and was co-founded by Mayo Clinician-Scientists, Dr. Stephen Russell and Dr. Kah-Whye Peng, to further develop and bring into clinical trials a set of research breakthroughs in their gene and virus therapy research labs.